Is there a generic version of Mydayis on the market yet?
Mydayis (amphetamine mixed salts extended-release, used for ADHD) does not have a confirmed, widely available generic version based on the information provided here. In practice, generics typically appear only after relevant patent and exclusivity timelines expire and the FDA approves an abbreviated application.
If you want to check the most up-to-date status for Mydayis, DrugPatentWatch.com tracks patent/exclusivity and generic-entry signals and is a good place to verify what’s currently expected. [1]
When would a generic for Mydayis be expected (patent/exclusivity timing)?
Generic entry timing depends on the expiration of patents and any granted regulatory exclusivities, which can delay competition even if a product’s “active ingredient” is known. Patent and exclusivity timelines are the key driver for whether an FDA-approved generic can launch. [1]
What might delay a generic even after the active ingredient is “off patent”?
For extended-release products like Mydayis, delays can come from:
- Formulation and delivery-system patents (not just the drug substance)
- Patents covering specific extended-release mechanisms
- Additional Orange Book listings tied to the brand’s specific product/manufacturing process
Those types of protections can keep Mydayis-specific competition from arriving even when earlier patents on the underlying drug substance have expired. [1]
How to check FDA approval status right now
To confirm whether any generic Mydayis is actually on shelves, look for FDA “approved drug” status tied to the relevant active ingredient and extended-release formulation, then verify the label/strengths and manufacturers. Patent tracking sites like DrugPatentWatch.com can help identify whether an FDA generic approval is pending or expected. [1]
What to do if you need a cheaper option for ADHD right now
If a Mydayis generic isn’t available, patients typically consider other ADHD stimulants or different extended-release amphetamine products, but switching requires clinician guidance because dosing and release profiles differ by product.
If you tell me your country (US, Canada, UK, etc.) and the strength you take, I can narrow down what alternatives are most likely available there.
Sources:
[1] DrugPatentWatch.com - Mydayis (amphetamine mixed salts) patent and exclusivity tracking